Bolt Biotherapeutics, Inc. (BOLT)
After hours: 02:29PM EST
Chart Events
Performance Outlook
| Previous Close | 9.10 |
| Open | 8.77 |
| Bid | 7.60 x 3200 |
| Ask | 9.74 x 1800 |
| Day's Range | 8.77 - 9.13 |
| 52 Week Range | 7.58 - 43.07 |
| Volume | 217,224 |
| Avg. Volume | 208,684 |
| Market Cap | 337.053M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.20 |
| Earnings Date | Nov 09, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 39.80 |
Fair Value
Related Research
- Bolt Biotherapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 02/12/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat9 months agoArgus Research
- GlobeNewswire
Bolt Biotherapeutics Announces Changes to its Board of Directors
REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced the appointments of Brian O’Callaghan and Frank D. Lee to the Board of Directors. With these additions, longtime Director Peter Moldt, Ph.D. is stepping down from the Board of Directors and
- GlobeNewswire
Bolt Biotherapeutics Presents New Preclinical Data on Three Pipeline Programs at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Presentation of preclinical data supporting the selection of BDC-2034, an ISAC targeting CEA, as Bolt Biotherapeutics’ second Boltbody™ ISAC development candidateDemonstration of the novel, multifunctional mechanism for an ISAC which combines PD-1/PD-L1 axis inhibition with TLR agonismIdentification of novel agonist antibodies targeting Dectin-2, now revealed as Bolt Biotherapeutics’ TAM1 target, designed to reprogram tumor-supportive macrophages into tumor-destructive macrophages REDWOOD CITY,
- GlobeNewswire
Bolt Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights
–BDC-1001 Phase 1/2 dose-escalation interim clinical trial update in HER2-expressing solid tumors to be presented at ESMO Immuno-Oncology Congress 2021–Strong cash position of $295.5 million expected to fund operations through the end of 2023 REDWOOD CITY, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of bo
